Drug eluting balloon industry market size
2024-06-11
Currently, devices that can be used for PCI procedures include bare metal stents, drug-eluting stents, fully degradable stents, and drug-eluting balloons. Bare metal stents have been gradually replaced by drug-eluting stents, and fully degradable stents still have limitations in material selection, product design, technology and other aspects. At present, drug-eluting stents are the mainstream stents, and the clinical application of drug-eluting balloons is increasing rapidly. Drug-eluting balloons have several potential advantages due to the absence of implants, their clinical application is rapidly increasing, and coupled with industry policy support for innovative products (such as encouraging and accelerating the review of innovative medical devices), they are in a stronger position to compete. In the future, with more competitors and competitive products entering the drug-eluting balloon market, the market education of the industry will be further strengthened, and the accurate and adequate pretreatment technology of lesions will continue to develop, and the scope of lesions that can be selected for application will be further expanded, promoting the increase of market penetration. With the promotion of the concept of "intervention without implantation" in recent years, the use of drug-eluting balloons has grown rapidly and is expected to maintain rapid growth.
According to Frost & Sullivan Forecast data, after drug-eluting balloons were first approved for the treatment of coronary artery disease in China, the use of them increased significantly from 7,500 in 2016 to 290,000in 2021. The market size is expected to further climb to 1.040 million in 2025, and is expected to reach 2.042 million in 2030.
Related recommend